922 related articles for article (PubMed ID: 31912279)
1. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
[TBL] [Abstract][Full Text] [Related]
2. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Moreau C; Danel V; Devedjian JC; Grolez G; Timmerman K; Laloux C; Petrault M; Gouel F; Jonneaux A; Dutheil M; Lachaud C; Lopes R; Kuchcinski G; Auger F; Kyheng M; Duhamel A; Pérez T; Pradat PF; Blasco H; Veyrat-Durebex C; Corcia P; Oeckl P; Otto M; Dupuis L; Garçon G; Defebvre L; Cabantchik ZI; Duce J; Bordet R; Devos D
Antioxid Redox Signal; 2018 Sep; 29(8):742-748. PubMed ID: 29287521
[TBL] [Abstract][Full Text] [Related]
3. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
[TBL] [Abstract][Full Text] [Related]
4. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
5. Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Devos D; Moreau C; Devedjian JC; Kluza J; Petrault M; Laloux C; Jonneaux A; Ryckewaert G; Garçon G; Rouaix N; Duhamel A; Jissendi P; Dujardin K; Auger F; Ravasi L; Hopes L; Grolez G; Firdaus W; Sablonnière B; Strubi-Vuillaume I; Zahr N; Destée A; Corvol JC; Pöltl D; Leist M; Rose C; Defebvre L; Marchetti P; Cabantchik ZI; Bordet R
Antioxid Redox Signal; 2014 Jul; 21(2):195-210. PubMed ID: 24251381
[TBL] [Abstract][Full Text] [Related]
6. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
7. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.
Kupershmidt L; Youdim MBH
Cells; 2023 Feb; 12(5):. PubMed ID: 36899898
[TBL] [Abstract][Full Text] [Related]
8. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
Grolez G; Moreau C; Sablonnière B; Garçon G; Devedjian JC; Meguig S; Gelé P; Delmaire C; Bordet R; Defebvre L; Cabantchik IZ; Devos D
BMC Neurol; 2015 May; 15():74. PubMed ID: 25943368
[TBL] [Abstract][Full Text] [Related]
9. Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease.
Riederer P; Monoranu C; Strobel S; Iordache T; Sian-Hülsmann J
J Neural Transm (Vienna); 2021 Oct; 128(10):1577-1598. PubMed ID: 34636961
[TBL] [Abstract][Full Text] [Related]
10. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Kontoghiorghes GJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
[TBL] [Abstract][Full Text] [Related]
11. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.
Martin-Bastida A; Ward RJ; Newbould R; Piccini P; Sharp D; Kabba C; Patel MC; Spino M; Connelly J; Tricta F; Crichton RR; Dexter DT
Sci Rep; 2017 May; 7(1):1398. PubMed ID: 28469157
[TBL] [Abstract][Full Text] [Related]
12. Role of Alcohol Drinking in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
Peng B; Yang Q; B Joshi R; Liu Y; Akbar M; Song BJ; Zhou S; Wang X
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230811
[TBL] [Abstract][Full Text] [Related]
13. Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.
Sun Y; Pham AN; Waite TD
ACS Chem Neurosci; 2018 May; 9(5):1118-1127. PubMed ID: 29381045
[TBL] [Abstract][Full Text] [Related]
14. Trial of Deferiprone in Parkinson's Disease.
Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
[TBL] [Abstract][Full Text] [Related]
15. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
Kaur D; Andersen JK
Aging Cell; 2002 Oct; 1(1):17-21. PubMed ID: 12882349
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
17. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease.
Mahoney-Sánchez L; Bouchaoui H; Ayton S; Devos D; Duce JA; Devedjian JC
Prog Neurobiol; 2021 Jan; 196():101890. PubMed ID: 32726602
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.
Zhang Q; Feng S; Zhao Y; Jin B; Peng R
J Biol Inorg Chem; 2021 Jun; 26(4):467-478. PubMed ID: 33963933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
